Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

global access

- PMLiVE

AI and over-digitalisation

The possibility of errors and the need to be cautious

- PMLiVE

Evaluating the Forces Shaping Women’s Healthcare

Gaps in women’s healthcare go beyond access and cost. Do clinicians have the tools they need to understand women’s health?

Medscape Education

- PMLiVE

Sandoz receives FDA approval for first denosumab biosimilars Wyost and Jubbonti

The biosimilars have been authorised for all indications covered by Amgen's reference medicines

- PMLiVE

Merck KGaA and C4 Therapeutics enter protein degrader partnership worth $756m

The collaboration will utilise C4T’s TORPEDO platform to target and degrade disease-associated proteins

- PMLiVE

Sanofi’s Xenpozyme not recommended by NICE for ultra-rare disease ASMD

An estimated 40 to 50 people in England are living with the lysosomal storage disorder

- PMLiVE

Novartis shares positive results for spinal muscular atrophy gene therapy Zolgensma

The company said the results support the use of the one-time therapy in older and heavier children

- PMLiVE

Drugmakers submit counteroffers to US Medicare pricing negotiations

New negotiated prices are set to be announced by 1 September 2024 and implemented in 2026

- PMLiVE

Incentivising innovation in antibiotics

Why current intellectual property and regulatory data exclusivity systems are failing to stimulate innovation in the field of antibiotics and antimicrobials

- PMLiVE

Fool me once

But just once – after that, you’re on your own

Top 10 HEOR trends – A detailed look at ISPOR’s 2024–2025 topics

Top 10 HEOR trends – A detailed look at ISPOR’s 2024–2025 topics

Specialists from across Mtech Access to look at each of ISPOR’s top 10 HEOR trends for 2024–2025. Jump in as the Mtech Access experts give their hot take on each...

Petauri Evidence

- PMLiVE

GSK’s Jemperli combination recommended by NICE as first-line endometrial cancer treatment

Approximately 580 patients will now be eligible for treatment with the PD-1 inhibitor

Bayer symbol

Bayer and BridgeBio enter European partnership worth up to $310m for ATTR-CM

The rare and progressive condition affects around 500,000 people worldwide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links